2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow KLH: new trials by email Literature Review of KLH trials Research Report on KLH
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis 23-PPV, 13-PCV Booster, Influenza Vaccine - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Hoffmann-La Roche | 102 | 2015-10-27 | 2024-03-26 |
| Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH - Glioblastoma, Small Cell Glioblastoma | Phase 3 | Completed | Celldex Therapeutics | 745 | 2011-11-01 | 2018-01-16 |
Brain Neoplasms (1) · Glioblastoma (1) · Gliosarcoma (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Neoplasms (1)
Celldex Therapeutics (1) · Hoffmann-La Roche (1)
Canada (2) · United States (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Colombia (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · India (1) · Israel (1) · Italy (1)
PMID 28844499, PMID 32727835, PMID 36346112
2015 (1)